Biomarker Amplification by Serum Carrier Protein Binding

Mehta, Arpita; Ross, Sally; Lowenthal, Mark S.; Fusaro, Vincent A.; Fishman, David A.; Petricoin, Emanuel F.; Liotta, Lance A.

doi:10.1155/2003/104879

Cited by 200 publications

(135 citation statements)

References 35 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…The retention of albumin in unfractionated serum samples may be essential to the diagnostic power of information gleaned from serum through this method. We recently demonstrated that albumin and other carrier proteins of high abundance avidly bind low molecular weight proteins and peptide fragments (33). Such low molecular weight molecules are the underpinning of the diagnostic patterns identified by this approach.…”

Section: Discussionmentioning

confidence: 99%

A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis

Stone

Rajapakse

Hoffman

et al. 2005

Arthritis & Rheumatism

Self Cite

View full text Add to dashboard Cite

Objective. To identify serum ion patterns that distinguish remission from active disease in patients with Wegener's granulomatosis (WG).Methods. Using sera collected in the WG Etanercept Trial, we selected samples from patients who either were undergoing a period of extended disease remission or had recent flares of active WG. Unfractionated samples were randomized into sets for training and testing, such that remission sera and active disease sera could be analyzed without batch bias. Molecular species within the sera were ionized by high-resolution, matrixassisted laser desorption ionization time-of-flight mass spectrometry. We then used a bioinformatics patternrecognition tool to identify optimal combinations of ions. During the training stage, the clinical data (remission versus active disease) were provided in association with the spectral data from each sample. In the testing stage, we performed blinded testing on a previously unexamined set of samples.Results Conclusion. This serum proteomic profiling approach appears to be useful in distinguishing between states of stable clinical remission and active disease.

show abstract

Section: Discussionmentioning

confidence: 99%

A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis

Stone

Rajapakse

Hoffman

et al. 2005

Arthritis & Rheumatism

Self Cite

View full text Add to dashboard Cite

show abstract

“…that overwhelm the less abundant signals. Methods to remove these abundant proteins have been developed; however, recent studies have found that many peptide fragments (potential biomarkers) circulate bound to albumin (24). Albumin acts as a sink or reservoir for these molecules and greatly prolongs their half-life from minutes to days (25).…”

Section: Step 3: Desired Site Of Clinical Measurementmentioning

confidence: 99%

Discovery of Protein Biomarkers for Renal Diseases

Hewitt¹,

Dear²,

Star³

2004

Journal of the American Society of Nephrology

270

150

View full text Add to dashboard Cite

Abstract. Animal models and human studies have been useful in dissecting the molecular mechanisms of renal disease and finding new disease targets; however, translation of these findings to new clinical therapeutics remains challenging. Difficulties with detecting early disease, measuring drug effectiveness, and the daunting cost of clinical trials hampers the development of new therapeutics for renal diseases. Many existing laboratory tests were discovered because of inspired recognition that a particular protein might prove useful in clinical practice. New unbiased genomic and proteomic techniques identify many constituents present in biologic samples and thus may greatly accelerate biomarker research. This review focuses on the steps needed to develop new biomarkers that are useful in laboratory and clinical investigations, with particular focus on new proteomic screening technologies. New biomarkers will speed the laboratory and clinical development of new treatments for renal diseases through mechanistic insights, diagnoses that are more refined, early detection, and enhanced proof of concept testing.

show abstract

“…These compounds may also reflect the physiologic state of the tumor and reveal the effects that the tumor has on the organism itself (2 ). Tumor-derived proteins that are produced in very low concentrations enter the circulation and bind to transport proteins (3,4 ). Sequestration of these peptides by carrier proteins that are present in high concentrations and have long half-lives, such as albumin, protects these markers from clearance and helps amplify their concentration in the circulation.…”

mentioning

confidence: 99%

Electron Spin Resonance Spectroscopy of Serum Albumin: A Novel New Test for Cancer Diagnosis and Monitoring

Kazmierczak

Gurachevsky²,

Matthes

et al. 2006

Clinical Chemistry

View full text Add to dashboard Cite

Background:Proteins released by tumor cells can bind to serum albumin, leading to structural and functional modifications. We used electron spin resonance (ESR) spectroscopy to measure these changes in serum albumin and evaluate their utility for the diagnosis and monitoring of cancer. Methods: We used an ESR spectrometer and 16-doxyl stearic acid as spin probe to measure conformational changes in albumin in blood samples from a population of healthy donors and volunteers (n ‫؍‬ 349), patients with a wide variety of hematologic and nonhematologic malignancy (n ‫؍‬ 135), and patients with chronic diseases such as gastrointestinal and pulmonary disease, diabetes, and cirrhosis (n ‫؍‬ 91). We added differing amounts of 16-doxyl stearic acid spin probe in ethanol to 50 L of serum from each patient to create 3 different aliquots that differed in concentration of spin probe and ethanol, then incubated the aliquots for 10 min at 37°C with continuous shaking. We measured the ESR spectra of each aliquot in triplicate and used proprietary software (MedInnovation GmbH) to evaluate the ESR spectrum for differences between cancer patients and the other groups. Results: The diagnostic sensitivity and specificity of this test were 87.4% and 95.7%, respectively, for differentiating healthy individuals from cancer patients and 87.4%, and 85.7% for differentiating cancer patients

show abstract

Biomarker Amplification by Serum Carrier Protein Binding

Cited by 200 publications

References 35 publications

A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis

A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis

Discovery of Protein Biomarkers for Renal Diseases

Electron Spin Resonance Spectroscopy of Serum Albumin: A Novel New Test for Cancer Diagnosis and Monitoring

Contact Info

Product

Resources

About